AstraZeneca Gets India Go-Ahead To Resume COVID-19 Vaccine Trials, US Nod Awaited

AstraZeneca plc AZN COVID-19 vaccine clinical trial is set to resume in India after local partner Serum Institute of India received the go-ahead from Indian regulators, Reuters reported Wednesday.

What Happened: The Drugs Controller General of India has approved the trial of the British drugmaker’s COVID-19 vaccine, a person familiar with the matter told Reuters. Trials have reportedly also restarted in Brazil and South Africa.

AstraZeneca has yet to get clearance from the Food and Drug Administration to resume trials in the United States, Bloomberg reported.

FDA Commissioner Stephen Hahn said during an online event, as per Bloomberg, that the regulator is “going to do very significant work with the company to figure out if there’s a significant safety issue or not.”

Why It Matters: The Cambridge, United Kingdom-based drugmaker resumed its vaccine trails in the United Kingdom last week after a temporary suspension due to a volunteer developing symptoms of a neurological disorder.

On Tuesday, Pfizer Inc PFE said its vaccine candidate caused no major side effects in trial volunteers participating in a late-stage study.

The Centers for Disease Control and Prevention asked states earlier in September to be ready to distribute two vaccine candidates, most likely ones being developed by Moderna Inc MRNA and Pfizer, according to the New York Times.

Posted In: clinical trialsCoronavirusCovid-19Food DReutersSerum Institute of IndiaVaccinesBiotechNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.